Details of the Drug

General Information of Drug (ID: DMGZQEF)

• Drug Name: Mifepristone
• Synonyms: Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma

Indication

Disease Entry	ICD 11	Status	REF
Cushing disease	5A70	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  G03XB01: Mifepristone
  G03XB: Progesterone receptor modulators
  G03X: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
  G03: SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
  G: GENITO URINARY SYSTEM AND SEX HORMONES
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 429.6
  Logarithm of the Partition Coefficient (xlogp); 3.8
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
  Bioavailability: The bioavailability of drug is 69% []
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.5 mL/min/kg [3]
  Elimination: The elimination of drug is 83% via feces and 9% via renal []
  Half-life: The concentration or amount of drug in body reduced by one-half in 18 hours [3]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 23.27704 micromolar/kg/day [4]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [3]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.45 L/kg [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hyperphagia	Not Available	NPY	OT4ICV3P	[5]

• Chemical Identifiers:
  Formula: C29H35NO2
  IUPAC Name: (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
  Canonical SMILES: CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
  InChI: InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
  InChIKey: VKHAHZOOUSRJNA-GCNJZUOMSA-N
• Cross-matching ID:
  PubChem CID: 55245
  ChEBI ID: CHEBI:50692
  CAS Number: 84371-65-3
  UNII: 320T6RNW1F
  DrugBank ID: DB00834
  TTD ID: D0Z4EI
  VARIDT ID: DR00714
  INTEDE ID: DR1091
  ACDINA ID: D00432
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8)	OTX1DWEF	DHB8_HUMAN	Gene/Protein Processing	[9]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[10]
15-hydroxyprostaglandin dehydrogenase (HPGD)	OTYZI6JB	PGDH_HUMAN	Gene/Protein Processing	[9]
17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6)	OTSB55D2	H17B6_HUMAN	Gene/Protein Processing	[9]
26S proteasome regulatory subunit 10B (PSMC6)	OTG8997V	PRS10_HUMAN	Gene/Protein Processing	[9]
5-hydroxytryptamine receptor 2B (HTR2B)	OTM1AD9J	5HT2B_HUMAN	Gene/Protein Processing	[9]
Acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase (B3GNT6)	OTAX8BNJ	B3GN6_HUMAN	Gene/Protein Processing	[9]
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[9]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Gene/Protein Processing	[9]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Gene/Protein Processing	[9]

Molecular Expression Atlas of This Drug

• The Studied Disease: Cushing disease
• ICD Disease Classification: 5A70

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.82E-01	-6.00E-02	-2.69E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mifepristone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Pasireotide.	Cushing syndrome [5A70]	[11]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Osilodrostat.	Cushing syndrome [5A70]	[11]

Coadministration of a Drug Treating the Disease Different from Mifepristone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Repaglinide	DM5SXUV	Moderate	Decreased metabolism of Mifepristone caused by Repaglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[12]
Glibenclamide	DM8JXPZ	Moderate	Decreased metabolism of Mifepristone caused by Glibenclamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[13]
Tolazamide	DMIHRNA	Moderate	Decreased metabolism of Mifepristone caused by Tolazamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[13]
Pioglitazone	DMKJ485	Moderate	Decreased metabolism of Mifepristone caused by Pioglitazone mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[13]
Glipizide	DMZA5PQ	Moderate	Decreased metabolism of Mifepristone caused by Glipizide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[13]
Ivosidenib	DM8S6T7	Major	Increased metabolism of Mifepristone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Midostaurin.	Acute myeloid leukaemia [2A60]	[11]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Idarubicin.	Acute myeloid leukaemia [2A60]	[11]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Arn-509.	Acute myeloid leukaemia [2A60]	[11]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[11]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Mifepristone caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[15]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Rivastigmine.	Alzheimer disease [8A20]	[11]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Mifepristone caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[16]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Mifepristone and Metronidazole.	Amoebiasis [1A36]	[12]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Ivabradine.	Angina pectoris [BA40]	[17]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Bepridil.	Angina pectoris [BA40]	[11]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Mifepristone caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[11]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Mifepristone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[13]
Cilostazol	DMZMSCT	Major	Decreased metabolism of Mifepristone caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[19]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Posaconazole.	Aspergillosis [1F20]	[13]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Terbutaline.	Asthma [CA23]	[11]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Pirbuterol.	Asthma [CA23]	[20]
Budesonide	DMJIBAW	Major	Antagonize the effect of Mifepristone when combined with Budesonide.	Asthma [CA23]	[13]
Salbutamol	DMN9CWF	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Salbutamol.	Asthma [CA23]	[12]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Formoterol.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[11]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[11]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Tindamax	DM3OWT4	Moderate	Decreased metabolism of Mifepristone caused by Tindamax mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Mifepristone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[21]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Mifepristone and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[11]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Mifepristone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Telithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Retigabine.	Behcet disease [4A62]	[11]
Cariprazine	DMJYDVK	Major	Decreased metabolism of Mifepristone caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[22]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Mifepristone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[13]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Loperamide.	Bowel habit change [ME05]	[23]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Eribulin.	Breast cancer [2C60-2C6Y]	[11]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Mifepristone due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[24]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Mifepristone caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Lapatinib.	Breast cancer [2C60-2C6Y]	[11]
HKI-272	DM6QOVN	Major	Decreased metabolism of Mifepristone caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Mifepristone caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Tucatinib	DMBESUA	Major	Decreased metabolism of Mifepristone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Mifepristone caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Mifepristone caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Mifepristone caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Trastuzumab Emtansine	DMU1LXS	Moderate	Decreased metabolism of Mifepristone caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Atorvastatin	DMF28YC	Moderate	Decreased metabolism of Mifepristone caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[12]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Mifepristone caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[26]
Corticotropin	DMP9TWZ	Major	Decreased metabolism of Mifepristone caused by Corticotropin mediated inhibition of CYP450 enzyme.	Chronic kidney disease [GB61]	[13]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Mifepristone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[11]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Dihydrocodeine	DMB0FWL	Moderate	Decreased metabolism of Mifepristone caused by Dihydrocodeine mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[19]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Mifepristone caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[28]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Isoproterenol.	Conduction disorder [BC63]	[20]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Mifepristone caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[12]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Halothane.	Corneal disease [9A76-9A78]	[11]
Ketamine	DMT5HA4	Moderate	Decreased metabolism of Mifepristone caused by Ketamine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[12]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Probucol.	Coronary atherosclerosis [BA80]	[11]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Clofazimine.	Crohn disease [DD70]	[11]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Mifepristone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[12]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Mifepristone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[13]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Sertraline.	Depression [6A70-6A7Z]	[11]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Mifepristone caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Mifepristone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Selegiline	DM6034S	Moderate	Decreased metabolism of Mifepristone caused by Selegiline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Escitalopram.	Depression [6A70-6A7Z]	[11]
OPC-34712	DMHG57U	Major	Decreased metabolism of Mifepristone caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[29]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Clomipramine.	Depression [6A70-6A7Z]	[11]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Doxepin.	Depression [6A70-6A7Z]	[11]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Mifepristone caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[30]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Mifepristone caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[19]
Oxybutynine	DMJPBAX	Moderate	Decreased metabolism of Mifepristone caused by Oxybutynine mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[12]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[11]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Mifepristone caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[31]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Deutetrabenazine.	Dystonic disorder [8A02]	[11]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Ingrezza.	Dystonic disorder [8A02]	[11]
Zonisamide	DM0DTF7	Moderate	Decreased metabolism of Mifepristone caused by Zonisamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Mifepristone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[13]
Tiagabine	DMKSQG0	Moderate	Decreased metabolism of Mifepristone caused by Tiagabine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Mifepristone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Mifepristone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[13]
Clonazepam	DMTO13J	Moderate	Decreased metabolism of Mifepristone caused by Clonazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Mifepristone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Mifepristone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[13]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Mifepristone caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[19]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Mifepristone caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[12]
Tazemetostat	DMWP1BH	Moderate	Decreased metabolism of Mifepristone caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[12]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Solifenacin.	Functional bladder disorder [GC50]	[11]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Mifepristone caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[32]
Tolterodine	DMSHPW8	Moderate	Decreased metabolism of Mifepristone caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[12]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Mifepristone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Mifepristone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Mifepristone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Ripretinib	DM958QB	Major	Decreased metabolism of Mifepristone caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[12]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[11]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Mifepristone caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[19]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Mifepristone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[13]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Mifepristone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[13]
Telaprevir	DMMRV29	Major	Decreased metabolism of Mifepristone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[13]
Daclatasvir	DMSFK9V	Major	Decreased metabolism of Mifepristone caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Mifepristone caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[13]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Mifepristone due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[33]
MK-1439	DM215WE	Minor	Decreased metabolism of Mifepristone caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Mifepristone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Mifepristone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Mifepristone caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Mifepristone caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Mifepristone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Mifepristone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Maraviroc	DMTL94F	Moderate	Decreased metabolism of Mifepristone caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Mifepristone caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[12]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Mifepristone caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[12]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Mifepristone caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[36]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Mifepristone caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Mifepristone caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Felodipine	DMOSW35	Moderate	Decreased metabolism of Mifepristone caused by Felodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Irbesartan	DMTP1DC	Moderate	Decreased metabolism of Mifepristone caused by Irbesartan mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Conivaptan	DM1V329	Major	Decreased metabolism of Mifepristone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[12]
Tolvaptan	DMIWFRL	Major	Decreased metabolism of Mifepristone caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[12]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Mifepristone caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[19]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Mifepristone caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[13]
TP-434	DM5A31S	Minor	Decreased metabolism of Mifepristone caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[37]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Mifepristone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[13]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Mifepristone caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Mifepristone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[13]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Mifepristone caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[13]
Triazolam	DMETYK5	Major	Decreased metabolism of Mifepristone caused by Triazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Zaleplon	DMGFWSM	Moderate	Decreased metabolism of Mifepristone caused by Zaleplon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Mifepristone caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[38]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Mifepristone caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Estazolam	DMZGXUM	Moderate	Decreased metabolism of Mifepristone caused by Estazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[19]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[11]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Mifepristone caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[39]
Naloxegol	DML0B41	Major	Decreased metabolism of Mifepristone caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[18]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Mifepristone caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[19]
Crizotinib	DM4F29C	Major	Decreased metabolism of Mifepristone caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
Brigatinib	DM7W94S	Major	Decreased metabolism of Mifepristone caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[40]
Ceritinib	DMB920Z	Major	Decreased metabolism of Mifepristone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Mifepristone caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[41]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Osimertinib.	Lung cancer [2C25]	[11]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Mifepristone caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Mifepristone caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[43]
Artemether	DM48QOT	Major	Decreased metabolism of Mifepristone caused by Artemether mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[12]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Halofantrine.	Malaria [1F40-1F45]	[11]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Hydroxychloroquine.	Malaria [1F40-1F45]	[11]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Primaquine.	Malaria [1F40-1F45]	[11]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[11]
Idelalisib	DM602WT	Major	Decreased metabolism of Mifepristone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
GDC-0199	DMH0QKA	Major	Decreased clearance of Mifepristone due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[12]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Mifepristone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[12]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[11]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Mifepristone caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[44]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Mifepristone caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[12]
Ponatinib	DMYGJQO	Moderate	Decreased metabolism of Mifepristone caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[12]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Mifepristone due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[12]
Selumetinib	DMC7W6R	Moderate	Decreased metabolism of Mifepristone caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[12]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Mifepristone and LGX818.	Melanoma [2C30]	[11]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Mifepristone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[13]
Dienestrol	DMBSXI0	Moderate	Decreased metabolism of Mifepristone caused by Dienestrol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[19]
Danazol	DML8KTN	Moderate	Decreased metabolism of Mifepristone caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[13]
Ubrogepant	DM749I3	Major	Decreased metabolism of Mifepristone caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[45]
Almogran	DM7I64Z	Moderate	Decreased metabolism of Mifepristone caused by Almogran mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[46]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Mifepristone caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[47]
Flibanserin	DM70DTN	Major	Decreased metabolism of Mifepristone caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[48]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Panobinostat.	Multiple myeloma [2A83]	[11]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Thalidomide.	Multiple myeloma [2A83]	[12]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Siponimod.	Multiple sclerosis [8A40]	[12]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Mifepristone and Fingolimod.	Multiple sclerosis [8A40]	[11]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Romidepsin.	Mycosis fungoides [2B01]	[11]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Nilotinib.	Myeloproliferative neoplasm [2A20]	[11]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Mifepristone caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
Busulfan	DMXYJ9C	Moderate	Decreased metabolism of Mifepristone caused by Busulfan mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Promethazine.	Nausea/vomiting [MD90]	[11]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Granisetron.	Nausea/vomiting [MD90]	[11]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Ondansetron.	Nausea/vomiting [MD90]	[11]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Mifepristone caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[49]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Mifepristone caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[12]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Mifepristone caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[50]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Lofexidine.	Opioid use disorder [6C43]	[11]
S-297995	DM26IH8	Moderate	Decreased metabolism of Mifepristone caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[12]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Mifepristone caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[12]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Rucaparib.	Ovarian cancer [2C73]	[11]
Ibuprofen	DM8VCBE	Moderate	Decreased metabolism of Mifepristone caused by Ibuprofen mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[13]
Hydrocodone	DMQ2JO5	Major	Decreased metabolism of Mifepristone caused by Hydrocodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[51]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Triclabendazole.	Parasitic worm infestation [1F90]	[11]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Pimavanserin.	Parkinsonism [8A00]	[11]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Mifepristone caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[12]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Mifepristone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[52]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Mifepristone and Famotidine.	Peptic ulcer [DA61]	[12]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Mifepristone caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[13]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[53]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Lefamulin.	Pneumonia [CA40]	[11]
Ergonovine	DM0VEC1	Major	Decreased metabolism of Mifepristone caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[18]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Mifepristone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[54]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Ritodrine.	Preterm labour/delivery [JB00]	[20]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Degarelix.	Prostate cancer [2C82]	[11]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Mifepristone and ABIRATERONE.	Prostate cancer [2C82]	[11]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Enzalutamide.	Prostate cancer [2C82]	[11]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Relugolix.	Prostate cancer [2C82]	[55]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Bicalutamide.	Prostate cancer [2C82]	[11]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Mifepristone caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[12]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Mifepristone caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[12]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[11]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Mifepristone caused by Selexipag mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[56]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Mifepristone caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[57]
Axitinib	DMGVH6N	Major	Decreased metabolism of Mifepristone caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[12]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Mifepristone caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[12]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[11]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Mifepristone caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Tofacitinib	DMBS370	Moderate	Decreased metabolism of Mifepristone caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Dexamethasone	DMMWZET	Major	Antagonize the effect of Mifepristone when combined with Dexamethasone.	Rheumatoid arthritis [FA20]	[13]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Quetiapine.	Schizophrenia [6A20]	[11]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Mesoridazine.	Schizophrenia [6A20]	[11]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Mifepristone caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[58]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Iloperidone.	Schizophrenia [6A20]	[11]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Paliperidone.	Schizophrenia [6A20]	[11]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Perphenazine.	Schizophrenia [6A20]	[11]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Amisulpride.	Schizophrenia [6A20]	[11]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Asenapine.	Schizophrenia [6A20]	[11]
Avanafil	DM75CXN	Major	Decreased metabolism of Mifepristone caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[12]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Vardenafil.	Sexual dysfunction [HA00-HA01]	[11]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Mifepristone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
LDE225	DMM9F25	Moderate	Decreased metabolism of Mifepristone caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[12]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Mifepristone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[19]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Mifepristone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Methylprednisolone	DM4BDON	Major	Antagonize the effect of Mifepristone when combined with Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[13]
Docetaxel	DMDI269	Major	Decreased clearance of Mifepristone due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[59]
Trabectedin	DMG3Y89	Moderate	Decreased metabolism of Mifepristone caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Mifepristone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[11]
Prednisolone	DMQ8FR2	Major	Decreased metabolism of Mifepristone caused by Prednisolone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[11]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Mifepristone caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[11]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Pitolisant.	Somnolence [MG42]	[11]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[11]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Mifepristone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[12]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Mifepristone due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[60]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Lenvatinib.	Thyroid cancer [2D10]	[11]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Papaverine.	Tonus and reflex abnormality [MB47]	[61]
Sirolimus	DMGW1ID	Major	Decreased metabolism of Mifepristone caused by Sirolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[18]
Tacrolimus	DMZ7XNQ	Major	Decreased metabolism of Mifepristone caused by Tacrolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[18]
Tolbutamide	DM02AWV	Moderate	Decreased metabolism of Mifepristone caused by Tolbutamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[13]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Mifepristone caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[12]
Elagolix	DMB2C0E	Moderate	Decreased clearance of Mifepristone due to the transporter inhibition by Elagolix.	Uterine fibroid [2E86]	[62]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[12]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Procainamide.	Ventricular tachyarrhythmia [BC71]	[11]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Propafenone.	Ventricular tachyarrhythmia [BC71]	[11]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Flecainide.	Ventricular tachyarrhythmia [BC71]	[11]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Mifepristone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[11]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mifepristone 300 mg tablet	300 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2805).
• [2] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [6] The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
• [7] Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
• [8] Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
• [9] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [10] Effect of the interaction between lipoxygenase pathway and progesterone on the regulation of hydroxysteroid 11-Beta dehydrogenase 2 in cultured human term placental trophoblasts. Biol Reprod. 2008 Mar;78(3):514-20.
• [11] Canadian Pharmacists Association.
• [12] Cerner Multum, Inc. "Australian Product Information.".
• [13] Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
• [14] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [15] Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
• [16] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [17] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
• [18] He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
• [19] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [20] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [21] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [22] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [23] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [24] Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [25] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
• [26] Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [27] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [28] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [29] Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [30] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [31] Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
• [32] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [33] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [34] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [35] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [36] Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
• [37] Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
• [38] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [39] Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
• [40] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [41] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [42] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [43] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [44] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [45] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [46] Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
• [47] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [48] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [50] Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
• [51] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
• [52] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [53] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [54] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [55] Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
• [56] Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [57] Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
• [58] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [59] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [60] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [61] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [62] Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.